• Publications
  • Influence
Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1.
Acyl coenzyme A:diacylglycerol acyltransferase 1 (DGAT1) is one of two known DGAT enzymes that catalyze the final step in mammalian triglyceride synthesis. DGAT1-deficient mice are resistant toExpand
  • 265
  • 14
  • PDF
Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands.
Acyl CoA:diacylglycerol acyltransferase (DGAT) is a ubiquitously expressed enzyme that catalyzes the final reaction in the major pathways of triglyceride synthesis. Mice lacking DGAT1 (Dgat(-/-))Expand
  • 126
  • 9
  • PDF
Determination of adipocyte size by computer image analysis.
Methods that allow rapid and accurate determination of adipocyte size are important to studies of energy and glucose metabolism. The direct measurement of adipocyte size by microscopy is widely used,Expand
  • 151
  • 8
  • PDF
Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension.
RATIONALE In 2005, lung allocation for transplantation in the United States changed from a system based on waiting time to a system based on the Lung Allocation Score (LAS). OBJECTIVES To study theExpand
  • 121
  • 8
Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease.
BACKGROUND Current practice guidelines emphasize the importance of attaining asthma control. We sought to quantify the degree of quality-of-life impairment associated with different levels of asthmaExpand
  • 185
  • 7
Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry.
BACKGROUND Pulmonary arterial hypertension (PAH) is a progressive and fatal disorder. Despite the emergence of effective therapy, PAH is commonly at an advanced stage when recognized. FactorsExpand
  • 164
  • 6
Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension.
Advances in our understanding of the basic pathophysiology of pulmonary arterial hypertension (PAH) has led to an expanding number of therapeutic options. The ultimate goals of therapy are toExpand
  • 84
  • 5
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.
BACKGROUND The Epidemiologic Study of Xolair (omalizumab): Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate-to-Severe Asthma (EXCELS) assessed the long-term safety ofExpand
  • 141
  • 3
Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme a:diacylglycerol acyltransferase 1 in white adipose tissue.
Acyl coenzyme A:diacylglycerol acyltransferase 1 (DGAT1) is one of two DGAT enzymes known to catalyze the final step in mammalian triglyceride synthesis. Mice deficient in DGAT1 are resistant toExpand
  • 116
  • 3
  • PDF
Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma.
OBJECTIVES Asthma can be associated with substantial productivity loss and activity impairment, particularly among those with the most severe disease. We sought to assess the performanceExpand
  • 96
  • 3